The reverse split has no fundamental economic impact — the stock price will adjust upward by 15x. Historically, sub-$1 biotechs perform poorly after reverse splits due to negative signaling (low comfort with ongoing viability). Monitor for potential selling pressure on the higher nominal price and next catalyst (trial data). The cross-filing 20-F shows a tiny $127M market cap and a novel treasury strategy around RAIN tokens, adding idiosyncratic risk.
Price Chart
Executive Summary
Enlivex announced a 1-for-15 reverse stock split effective July 9, 2026, reducing outstanding shares from 252,480,222 to ~16,832,015. This is a technical measure to maintain Nasdaq listing compliance and does not change the company's fundamentals. The filing provides no new clinical, financial, or operational data.
Key Facts
- Reverse split ratio set at 1-for-15, effective July 9, 2026.
- Outstanding shares will decrease from 252,480,222 to approximately 16,832,015.
- Authorized shares reduced from 2,375,000,000 to 158,333,334.
- Par value increases from NIS 0.40 to NIS 6.00 per share.
- No fractional shares; all fractional shares rounded up.
- Warrant and option exercise prices adjusted proportionally.
- Ticker symbol remains ENLV on Nasdaq Capital Market.
- Shareholder ownership percentages unchanged (except fractional rounding).
Financial Impact
No change in market capitalization; purely mechanical share consolidation. No new capital raised or deployed.
Risk Factors
- Negative signaling from reverse split often leads to post-split stock decline (historical pattern).
- Enlivex has an unusual treasury strategy based on prediction markets tokens (RAIN), which introduces volatility unrelated to clinical pipeline.
- Very high share count pre-split (252M) indicates prior heavy dilution — the reverse split may be a precursor to further capital raises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-075756 |
| Document: ea0297195-6k_enlivex.htm | 0001213900-26-075756 |
| Document: 0001213900-26-075756-index-headers.html | 0001213900-26-075756 |
| Document: 0001213900-26-075756-index.html | 0001213900-26-075756 |
| Document: 0001213900-26-075756.txt | 0001213900-26-075756 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 22, 2026 4d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 19, 2026 7d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Oct 19, 2026 7d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.56 (+398.99%) |
Sep 22, 2026 4w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.56 (+296.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.56 (+62.33%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.56 (+31.53%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.56 (+13.99%) |
Jul 28, 2026 12w ago | 6-K | $2.24 $2.17 | ▲ +3.13% | ▲ +5.39% | $2.56 (−14.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers